BPC-157 and TB-500 are two of the most widely studied research peptides, and they are often discussed together. They are not related. BPC-157 is a 15-amino-acid fragment of a protein found in gastric juice. TB-500 is a 43-amino-acid peptide identical in sequence to thymosin beta-4, a protein that binds actin inside cells.
Why Are BPC-157 and TB-500 Always Compared?
BPC-157 and TB-500 turn up together so often, in research catalogs and in combination blends, that they can look like two versions of the same thing. In fact they come from different proteins, differ more than threefold in size, and are studied through different mechanisms.
That difference is the reason they are compared at all. When two peptides act on related cell behaviors through different routes, researchers can study each route on its own and then ask what happens when both are present. Everything below stays at the level of structure and preclinical research. None of the findings described here establish effects in humans.
BPC-157 vs TB-500 at a Glance
The specifications Validated Peptides publishes for each peptide, set side by side:
| Specification | BPC-157 | TB-500 |
|---|---|---|
| Origin | Partial sequence of a gastric juice protein | Same sequence as thymosin beta-4 |
| Length | 15 amino acids | 43 amino acids |
| Molecular weight | 1,419.53 g/mol | 4,963.44 g/mol |
| Molecular formula | C62H98N16O22 | C212H350N56O78S |
| CAS number | 137525-51-0 | 77591-33-4 |
| N-terminus | Free | Acetylated (Ac-) |
| Main research focus | Growth factor receptor and migration signaling | Actin binding and cell migration |
| Vial sizes | 5 mg, 10 mg | 5 mg, 10 mg |
The formulas and CAS numbers match the PubChem entries for BPC-157 and for thymosin beta-4. Both peptides are also sold together as the Wolverine Blend.
Where Each Peptide Comes From
BPC-157
BPC stands for body protection compound. The full protein was discovered in, and isolated from, human gastric juice, and BPC-157 is a 15-amino-acid partial sequence of it (Chang et al., 2011). The research peptide is synthetic. Its sequence, as Validated Peptides lists it, is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
TB-500
Thymosin beta-4 was first isolated from calf thymus and was initially thought to be a thymic hormone. In 1991, researchers studying an actin-binding peptide from human platelets, named Fx, sequenced it and found it identical to thymosin beta-4 (Safer et al., 1991). The same work noted its wide distribution and high concentration inside many cell types. TB-500 is the research name used for the synthetic peptide, and Validated Peptides lists it with the full 43-amino-acid thymosin beta-4 sequence and an acetylated N-terminus.
How Their Structures Differ
The most obvious difference is size. TB-500 is 43 amino acids long and BPC-157 is 15, and the molecular weights reflect it: about 4,963 g/mol against about 1,420 g/mol.
Size also matters at the bench, in a way that is easy to miss. Peptides are sold and weighed by mass, but they act as individual molecules. One milligram of BPC-157 contains roughly 3.5 times as many molecules as one milligram of TB-500, because each BPC-157 molecule weighs about 3.5 times less. Two vials of equal weight do not hold equal numbers of molecules, which matters when a study compares the two at the same concentration.
The sequences are also built differently. BPC-157 carries four proline residues in its 15 positions, three of them in a row near the start. Thymosin beta-4 is acidic, rich in lysine and glutamic acid, and is described as heat-stable (Safer et al., 1991). The acetyl group on its N-terminus is part of the sequence Validated Peptides lists for TB-500.
What Researchers Study Each For
BPC-157: signaling at the cell surface
Much of the mechanistic work on BPC-157 looks at how it changes signaling that controls cell movement and blood vessel formation. In a 2011 study, BPC-157 increased the migration and spreading of rat tendon fibroblasts in culture, increased F-actin formation, and raised phosphorylation of FAK and paxillin, two proteins that link the cell to its surroundings, without changing their total amounts. It did not directly change fibroblast proliferation (Chang et al., 2011).
A 2017 study looked at blood vessel formation. In human vascular endothelial cells, BPC-157 increased expression of VEGFR2, a receptor for vascular endothelial growth factor, but not of VEGF-A itself, promoted internalization of the receptor, and activated the VEGFR2-Akt-eNOS signaling pathway (Hsieh et al., 2017).
TB-500: actin inside the cell
Thymosin beta-4 works on a different level. It binds G-actin, the single-molecule form of actin, in a one-to-one complex and stops it from assembling into filaments (Safer et al., 1991). By holding actin in reserve, it influences how readily a cell can build the filaments it needs to change shape and move. Reviews describe thymosin beta-4 as promoting cell migration and as being released by platelets, macrophages and other cell types after injury (Goldstein et al., 2012).
Where the Research Overlaps
Both peptides end up being studied around the same cell behaviors: migration, attachment and the formation of new blood vessels. They reach those behaviors from opposite directions. BPC-157 research centers on receptor and kinase signaling, while thymosin beta-4 research centers on the actin supply inside the cell.
A 2026 study compared them directly. In a rat model of Achilles tendon repair, groups received BPC-157, TB-500 or both, and tendons were assessed by biomechanical testing, histology and collagen staining. Both single-peptide groups showed improved histological scores against controls, and the TB-500 group also showed a significant biomechanical difference. The combination did not show an additional effect beyond either peptide alone, and the authors suggested the two may converge on shared downstream pathways, a hypothesis they note still needs testing (Biçer et al., 2026).
That result is a useful reminder that two mechanisms do not automatically add up. It is one study in one model, and it is the kind of question that single-peptide controls exist to answer.
What the Evidence Base Looks Like
Both peptides have a large preclinical literature and very little human data. A 2025 review of BPC-157 found broad support in animal models, through pathways including VEGFR2 and Akt-eNOS, but described human data as extremely limited and concluded that BPC-157 should be considered investigational (McGuire et al., 2025).
For a laboratory, the practical reading is that both are research tools with well-described mechanisms in cell and animal models. Neither is a medicine, and Validated Peptides supplies both for research use only.
Single Peptides or the Wolverine Blend
The choice between separate vials and a combined vial follows from the study design. Single peptides are the starting point for measuring one mechanism cleanly, and for running controls alongside a combination.
The Wolverine Blend combines BPC-157 and TB-500 in one 20 mg vial for work that studies both together. Its lot report confirms the identity of both components.
Whichever format a study uses, equal mass does not mean equal molecules. Because of the size difference, a study that needs equal molar amounts of each peptide has to account for it when preparing solutions.
What to Check When Sourcing BPC-157 or TB-500
Because both peptides are sold widely under the same short names, the first check is that a listing describes the molecule it claims to. The useful identifiers are the ones in the table above: length, molecular weight, formula and CAS number. A listing for TB-500 should also say whether it is the full 43-amino-acid sequence, since the name is not used consistently across the market.
From there, the lot report does the work:
- The lot number on the report matches the lot printed on the vial.
- Identity is confirmed by a stated method, so the peptide in the vial is confirmed rather than assumed.
- Purity is printed against its acceptance limit, so the margin is visible.
- Net peptide content is reported. For two peptides of such different size, it is the figure that lets a lab work out molar amounts.
- For a blend, the identity line names every component.
- The report can be checked with the testing laboratory, as set out in the guide to verifying a peptide COA.
How Each BPC-157 and TB-500 Lot Is Verified
Identity is the first line to read on any of these reports. For the Wolverine Blend, it has to confirm both peptides, not one.
Validated Peptides publishes the current reports on each product page and in the Certificate of Analysis library. The current lots:
| Product | Lot | Tested | HPLC purity | Net peptide content | Identity (HPLC) |
|---|---|---|---|---|---|
| BPC-157 10 mg | BPC157-10MG-BA-825 | August 12, 2026 | 99.49% | 10.6 mg | BPC-157 confirmed |
| TB-500 10 mg | 000329W | July 31, 2026 | 99.16% | 10.28 mg | TB-4 confirmed |
| Wolverine Blend 20 mg | WOLV-20MG-BA-361 | August 12, 2026 | 99.73% | 20.98 mg | BPC-157, TB-500 confirmed |
The BPC-157 and Wolverine Blend lots also report heavy metals not detected by ICP-MS, no growth on a PCR microbial screen, endotoxin at no more than 0.05 EU/mL by the USP <85> method, and a pass on a fentanyl screen. The TB-500 lot reports a pass on a fentanyl screen alongside its purity, content and identity results. Testing is carried out by an independent third party laboratory.
The guide to reading a peptide COA explains each line of a report.
Storing BPC-157 and TB-500 in the Lab
Both peptides ship as lyophilized (freeze-dried) powder. The published handling guidance for each is to store it in a cool, dry place away from light, refrigerated at 2 to 8°C, and to avoid repeated freeze-thaw cycles.
When a protocol calls for either peptide in solution, it is reconstituted with sterile water or bacteriostatic water, and the solution is stored according to the compound documentation. The guide to storing peptide vials in the fridge covers vial handling from powder through reconstitution.
Where BPC-157 and TB-500 Sit in Peptide Research
BPC-157 and TB-500 are two well-characterized tools that reach related cell behaviors by different routes: one through receptor and kinase signaling, the other through the actin supply inside the cell. That is what makes them worth comparing, and what makes combination studies worth running with proper controls.
As direct comparisons like the 2026 tendon model accumulate, the open question is less which peptide is more active and more how, and whether, their mechanisms interact. Lot documentation that confirms each peptide in the vial is what makes those comparisons reliable.
Frequently Asked Questions
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid partial sequence of a protein from gastric juice, studied mainly for growth factor receptor and migration signaling. TB-500 matches the 43-amino-acid sequence of thymosin beta-4, which binds actin inside cells. They are unrelated peptides that are often studied side by side, and both are sold for research use only.
Is TB-500 the same as thymosin beta-4?
Validated Peptides lists TB-500 with the full 43-amino-acid sequence of thymosin beta-4 and an acetylated N-terminus, with a molecular weight of 4,963.44 g/mol. Its lot report confirms identity as TB-4. TB-500 is the name used for the synthetic research peptide.
Which is bigger, BPC-157 or TB-500?
TB-500 is about 3.5 times larger: 43 amino acids and 4,963.44 g/mol, against 15 amino acids and 1,419.53 g/mol for BPC-157. As a result, one milligram of BPC-157 contains roughly 3.5 times as many molecules as one milligram of TB-500, which matters when comparing them at equal concentrations.
Where does BPC-157 come from?
BPC-157 is a 15-amino-acid partial sequence of body protection compound, a protein discovered in and isolated from human gastric juice. The research peptide is made synthetically. Validated Peptides lists its sequence as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a formula of C62H98N16O22 and a molecular weight of 1,419.53 g/mol.
Are BPC-157 and TB-500 studied together?
Yes. A 2026 rat tendon model compared each peptide alone and the two combined, and the combination showed no additional effect over either alone in that model. Validated Peptides also sells both in one vial as the Wolverine Blend, alongside the single peptides that serve as controls.
How should BPC-157 and TB-500 be stored?
Both should be kept as lyophilized powder in a cool, dry place away from light, refrigerated at 2 to 8 degrees Celsius, with repeated freeze-thaw cycles avoided. Laboratories reconstitute them with sterile or bacteriostatic water when a protocol calls for a solution, and store that solution according to the compound documentation.
References
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 2011;110(3):774-780. https://doi.org/10.1152/japplphysiol.00945.2010
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine, 2017;95(3):323-333. https://doi.org/10.1007/s00109-016-1488-y
- Safer D, Elzinga M, Nachmias VT. Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. Journal of Biological Chemistry, 1991;266(7):4029-4032. https://pubmed.ncbi.nlm.nih.gov/1999398/
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy, 2012;12(1):37-51. https://doi.org/10.1517/14712598.2012.634793
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study. Joint Diseases and Related Surgery, 2026;37(3):822-837. https://doi.org/10.52312/jdrs.2026.2951
- McGuire FP, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 2025;18(12):611-619. https://doi.org/10.1007/s12178-025-09990-7